Another study showed that erdafitinib and anti-PD-1 combination treatment induced changes in the tumour microenvironment to enhance antitumour response and survival in an FGFR2-mutant lung cancer mouse model [112]. The gene discussed is FGFR2; the disease is lung carcinoma.